Bryostatin 1 is one of a series of cyclic macrolides isolated from the marine bryozoan Bugula neritina (Order Cheilostomata), and a potent modulator of Protein Kinase C (PKC).
Bryostatin 1 has undergone several Phase I and Phase II clinical trials against melanomas, lymphomas and renal cancers by the National Cancer Institute in the United States and by the Cancer Research Campaign in Great Britain. In vitro studies have shown that Bryostatin 1 is a potent antileukemic agent that works by a unique and unusual mechanism. This compound exhibits selective activity against leukemias and directly stimulates bone marrow progenitor cells to form colonies that functionally activate neutrophils. This combined activity is unusual because most cytotoxic anticancer agents are toxic to bone marrow. The mechanism of activity is unknown but it may be related to the ability of the bryostatins to modulate the protein kinase C receptor.
|Product Type:||Small Molecule|
|Format:||White crystalline solid|
|Purity:||>99 % determined by HPLC|
|Solubility:||Soluble in methanol and ethanol|
|Stability:||Stable as a solid over extended period at -20C.|
|Storage:||-20C, avoid exposure to oxygen and direct sunlight|
Bryostatin 1 HPLC Chromatogram.
Purification Notes: Purified using near-critical and supercritical fluids as an alternate to conventional organic solvents during a sequence of phase extraction and chromatographic purification steps.
If you publish research with this product, please let us know so we can cite your paper.